Enzo Biochem, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Segment reporting (Tables)

Segment reporting (Tables)

6 Months Ended

Jan. 31, 2014

Schedule of Segment Reporting Information, by Segment [Table Text Block]

The following financial information represents the operating results of the reportable segments of the Company:

Three months ended January 31, 2014
	Clinical Labs			Life Sciences			Therapeutics			Other			Consolidated
Revenues:
Clinical laboratory services	$	13,848			—			—			—		$	13,848
Product revenues		—		$	8,054			—			—			8,054
Royalty and license fee income		—			1,026			—			—			1,026
		13,848			9,080			—			—			22,928
Operating expenses:
Cost of clinical laboratory services		9,292			—			—			—			9,292
Cost of product revenues		—			3,865			—			—			3,865
Research and development		3			543		$	286			—			832
Selling, general and administrative		4,981			3,318			—		$	1,785			10,084
Provision for uncollectible accounts receivable		920			(8	)		—			—			912
Legal		142			15			—			1,339			1,496
Total operating expenses		15,338			7,733			286			3,124			26,481

Operating income (loss)		(1,490	)		1,347			(286	)		(3,124	)		(3,553	)

Other income (expense)
Interest		(11	)		3			—			(44	)		(52	)
Other		9			(6	)		—			12			15
Foreign currency gain		—			20			—			—			20
Income (loss) before income taxes	$	(1,492	)	$	1,364		$	(286	)	$	(3,156	)	$	(3,570	)

Depreciation and amortization included above	$	355		$	621		$	2		$	24		$	1,002

Share-based compensation included in above:
Cost of clinical laboratory services	$	2			—			—			—		$	2
Research and development		—			—			—			—			—
Selling, general and administrative		9		$	5			—		$	93			107
Total	$	11		$	5			—		$	93		$	109

Capital expenditures	$	103		$	7		$	—		$	—		$	110

Three months ended January 31, 2013
	Clinical Labs			Life Sciences			Therapeutics			Other			Consolidated
Revenues:
Clinical laboratory services	$	13,320			—			—			—		$	13,320
Product revenues		—		$	7,876			—			—			7,876
Royalty and license fee income		—			1,014			—			—			1,014
		13,320			8,890			—			—			22,210
Operating expenses:
Cost of clinical laboratory services		9,425			—			—			—			9,425
Cost of product revenues		—			4,143			—			—			4,143
Research and development		86			570		$	312			—			968
Selling, general and administrative		4,911			4,081			—		$	1,900			10,892
Provision for uncollectible accounts receivable		1,213			122			—			—			1,335
Legal		51			31			—			1,359			1,441
Total operating expenses		15,686			8,947			312			3,259			28,204

Operating income (loss)		(2,366	)		(57	)		(312	)		(3,259	)		(5,994	)

Other income (expense)
Interest		(13	)		5			—			1			(7	)
Other		17			17			—			9			43
Foreign currency gain		—			104			—			—			104
Income (loss) before income taxes	$	(2,362	)	$	69		$	(312	)	$	(3,249	)	$	(5,854	)

Depreciation and amortization included above	$	355		$	799		$	7		$	25		$	1,186

Share-based compensation included in above:
Cost of clinical laboratory services	$	2			—			—			—		$	2
Research and development		—			1			—			—			1
Selling, general and administrative		11		$	6			—		$	140			157
Total	$	13		$	7			—		$	140		$	160

Capital expenditures	$	241		$	87		$	—		$	—		$	328

Six months ended January 31, 2014
	Clinical Labs			Life Sciences		Therapeutics			Other			Consolidated
Revenues:
Clinical laboratory services	$	28,707			—		—			—		$	28,707
Product revenues		—		$	15,717		—			—			15,717
Royalty and license fee income		—			2,637		—			—			2,637
		28,707			18,354		—			—			47,061
Operating expenses:
Cost of clinical laboratory services		19,001			—		—			—			19,001
Cost of product revenues		—			7,712		—			—			7,712
Research and development		14			1,069	$	566			—			1,649
Selling, general and administrative		10,031			6,813		—		$	3,768			20,612
Provision for uncollectible accounts receivable		1,764			20		—			—			1,784
Legal		290			37		—			2,550			2,877
Total operating expenses		31,100			15,651		566			6,318			53,635

Operating income (loss)		(2,393	)		2,703		(566	)		(6,318	)		(6,574	)

Other income (expense)
Interest		(22	)		8		—			(100	)		(114	)
Other		27			21		—			28			76
Foreign currency gain		—			317		—			—			317
Income (loss) before income taxes	$	(2,388	)	$	3,049	$	(566	)	$	(6,390	)	$	(6,295	)

Depreciation and amortization included above	$	710		$	1,262	$	6		$	49		$	2,027

Share-based compensation included in above:
Cost of clinical laboratory services	$	4			—		—			—		$	4
Research and development		—		$	1		—			—			1
Selling, general and administrative		19			9		—		$	179			207
Total	$	23		$	10		—		$	179		$	212

Capital expenditures	$	362		$	82	$	—		$	—		$	444

Six months ended January 31, 2013
	Clinical Labs			Life Sciences		Therapeutics			Other			Consolidated
Revenues:
Clinical laboratory services	$	28,497			—		—			—		$	28,497
Product revenues		—		$	16,309		—			—			16,309
Royalty and license fee income		—			3,033		—			—			3,033
		28,497			19,342		—			—			47,839
Operating expenses:
Cost of clinical laboratory services		19,135			—		—			—			19,135
Cost of product revenues		—			8,327		—			—			8,327
Research and development		175			1,175	$	629			—			1,979
Selling, general and administrative		9,873			8,353		—		$	4,082			22,308
Provision for uncollectible accounts receivable		2,769			160		—			—			2,929
Legal		158			36		—			2,948			3,142
Total operating expenses		32,110			18,051		629			7,030			57,820

Operating income (loss)		(3,613	)		1,291		(629	)		(7,030	)		(9,981	)

Other income (expense)
Interest		(22	)		4		—			3			(15	)
Other		24			20		—			12			56
Foreign currency gain		—			333		—			—			333
Income (loss) before income taxes	$	(3,611	)	$	1,648	$	(629	)	$	(7,015	)	$	(9,607	)

Depreciation and amortization included above	$	663		$	1,604	$	14		$	55		$	2,336

Share-based compensation included in above:
Cost of clinical laboratory services	$	4			—		—			—		$	4
Research and development		—		$	1		—			—			1
Selling, general and administrative		22			6		—		$	268			296
Total	$	26		$	7		—		$	268		$	301

Capital expenditures	$	420		$	170	$	—		$	—		$	590

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References + Details